Site Name: UK – London – New Oxford Street, Belgium-Wavre, USA - Pennsylvania - Upper Providence
Posted Date: Nov 13 2024
Senior Director, Global Real-World Evidence & Health Outcomes Research Lead - RSV
For drugs to be successful, there must be robust health outcomes data to support launch optimization, reimbursement and maintain market position. Specifically, evidence must be maintained throughout the product lifecycle as standard of care changes, new competitors are introduced, and patents expire on existing competitors. The landscape is evolving quickly as trials demonstrating efficacy in an area of unmet need may receive expedited review, or orphan product status designation which affects both GSK and competitors launch timelines and approval requirements. More and more of our customers are developing sophisticated internal health outcomes capabilities and access to real world data that can be used to better understand unmet needs and real-world effectiveness of our medicines. We need to better understand how our customers define value and to effectively collaborate with them to ensure we are generating value evidence data that includes real world evidence and cost effectiveness analysis that is impactful for payers, health systems, providers, and patients.
The role of Senior Director, Global Real-World Evidence & Health Outcomes Research Lead is critical to achieving this ambition by ensuring that each medicine GSK brings to market is supported by scientifically credible, high-quality evidence that drives competitiveness and strong evidence-based product positioning, value propositions and value-based pricing. The role is essential for the alignment of evidence with the requirements of customers responsible for marketing authorization, recommendation and reimbursement leading to successful patient access, product use and commercial success.
Within this organisation as the VP, Head of Global Real-World Evidence & Health Outcomes Research, Sulabha Ramachandran will be leading a team which incorporates the legacy VEO/Non-Interventional Studies capabilities teams under a newly evolved name that more closely reflects their purpose and the research they deliver.
Key Responsibilities:
* Serve as single point accountable lead for a medium complexity priority asset and have expertise in real-world evidence and other non-interventional study methods.
* Engage closely with medical and matrix stakeholders and partner effectively in data generation plan (DGP) planning, design, execution, translation, and dissemination for the asset.
* Provide guidance for best practice in real world evidence/NIS methodologies, including enabling external scientific advice, ensuring appropriate protocol review committee’s advice sought and incorporated.
* Drive innovation and inform ideas and options through effective engagement with external experts, clinical guideline groups, HTA agencies, methodology and policy forums.
* Integrate understanding of the evolving global NITAG, Health Technology Assessment, clinical guidelines groups, policy decision makers and payer environment.
* Negotiate with key stakeholders regarding evidence development for the asset, weighing risks and benefits.
* Deliver materials to inform internal governance decision making.
* Facilitate alignment and partnership within the complex stakeholder matrix.
* Represent GSK in external collaborations and engagement with scientific partners, reimbursement bodies and other decision makers.
* Drive quality and compliance through the team to ensure trust in the evidence delivered.
* Ensure studies are delivered according to plan and within budget.
Basic Qualifications:
We are looking for professionals with these required skills to achieve our goals:
* PhD, PharmD or equivalent level qualification in Health outcomes, patient reported outcomes, health economics, epidemiology, pharmacy, health, or life sciences.
* Considerable experience working in global pharmaceuticals in a leadership role.
* Methods expertise to guide and lead team in delivering robust payer evidence deliverables.
* Knowledge of healthcare markets, health technology assessment agencies, and reimbursement decision making globally.
* Understanding of how health economics, health outcomes, comparative effectiveness research, PRO research can be applied at local decision-making levels.
* Deep knowledge and strong communication skills for interpreting and translating complex concepts to impact decision making.
* Excellent knowledge of drug development and therapy area.
* Self-motivated with the ability to work independently and develop credibility with colleagues.
* Experience leading a portfolio of projects and influencing senior stakeholder groups.
Preferred Qualifications:
* Advanced scientific or business degree specialized in Health Outcomes or similar.
* Experience in above country and in country roles.
* Direct Payer experience.
* Launch experience.
* Portfolio of high value publications and/or scientific promotions.
Closing Date for Applications: 27 November 2024 (EOD)
Please take a copy of the Job Description, as this will not be available post closure of the advert. When applying for this role, please use the ‘cover letter’ of the online application or your CV to describe how you meet the competencies for this role, as outlined in the job requirements above.
Why GSK?
GSK is a global biopharma company with a special purpose – to unite science, technology and talent to get ahead of disease together. We prevent and treat disease with vaccines, specialty and general medicines. Our success depends on our people. We want GSK to be a place where people feel inspired, encouraged and challenged to be the best they can be.
As an Equal Opportunity Employer, we are open to all talent. In the US, we also adhere to Affirmative Action principles.
We believe in an agile working culture for all our roles. If flexibility is important to you, we encourage you to explore with our hiring team what the opportunities are.
#J-18808-Ljbffr